A commentary by Calvin Meaney urges discontinuation of outdated tests that are imprecise or disadvantage Black patients.

The Phase III study FIND-CKD ( NCT05047263) — investigating the efficacy and safety of KERENDIA ® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic ...

Bayer BAYRY announced that finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone in expanding its use to patients with non-diabetic chronic kidney disease ...

Removing race from the eGFR had a big impact, resulting in 5.3 more kidney transplants per 1000 Black candidates.

Researchers are reporting success after a new effort to reverse racial bias against Black kidney patients is paying off.

MISSION HILLS, LOS ANGELES (KABC) -- A medical test for kidney function that adjusts its results for race is coming under increased scrutiny. Experts are saying the results for African-American ...

DEAR DR. ROACH: I am a 73-year-old female. A recent blood test returned an eGFR (estimated glomerular filtration rate) of 59. My physician’s nurse told me that the test was normal. When I asked her ...

A new study published in the Journal American Medical Association showed that patients with an Cystatin C based estimated ...

March is National Kidney Month. Learn how to protect your kidney health, recognize symptoms, and reduce your risk of disease.

Bayer announces finerenone meets primary endpoint in pivotal phase III FIND-CKD study in patients with non-diabetic chronic kidney disease: Berlin Tuesday, March 17, 2026, 15:00 H ...